Delisting riskPopularity #3,932
Oncolytics Biotech (ONCY)
Develops pelareorep, a double-stranded RNA immunotherapy for gastrointestinal tumors.
$0.6769
vs last close−0.04 (−5.10%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 3.96% | 3.98M ADS | |
|---|---|---|---|
| 78 holders · as of Jun 30, 2026 | |||
| Other | 96.04% | 96.38M ADS | |
| remainder | |||
100.36M ADS as of Sep 14, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13F, as of Jun 30, 2026
78 holders · 3.98M shares · 29 new positions · 42 increased · 9 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Marshall Wace, LLP | 745.4K | 0.74% | −114.5K | Aug 13, 2026 |
| XTX Topco Ltd | 260.9K | 0.26% | +260.9Knew | Aug 14, 2026 |
| Seeds Investor LLC | 258.3K | 0.26% | +258.3Knew | Aug 12, 2026 |
| International Assets Investment Management, LLC | 201.3K | 0.20% | +201.3Knew | Jul 22, 2026 |
| Connective Capital Management, LLC | 185.7K | 0.19% | +185.7Knew | Aug 13, 2026 |
| Goldman Sachs Group Inc | 169.9K | 0.17% | +169.9Knew | Aug 14, 2026 |
| Tocqueville Asset Management L.P. | 147.0K | 0.15% | +147.0Knew | Aug 10, 2026 |
| Everhart Financial Group, Inc. | 140.9K | 0.14% | +140.9Knew | Jul 9, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Anson Funds Management LP | 7.00% | 7.65M | 13G | Nov 14, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 12, 2026 | Jared Kellydirector, officer: Chief Executive Officer | Purchase | 5,050 | $0.9600 | 114,050 |
| Mar 11, 2026 | James T. Parsonsdirector | Purchase | 10,000 | $1.03 | 41,849 |
| Feb 12, 2026 | Patricia S. Andrewsdirector | Purchase | 35,400 | $0.8557 | 78,128 |
| Feb 11, 2026 | Andrew Aromandoofficer: Chief Business Officer | Purchase | 29,600 | $0.8587 | 55,100 |
| Feb 11, 2026 | Bernd R. Seizingerdirector | Purchase | 60,000 | $0.8265 | 526,991 |
| Feb 12, 2026 | Bernd R. Seizingerdirector | Purchase | 40,000 | $0.8466 | 566,991 |
| Feb 12, 2026 | Allison Hagermanofficer: VP, Product Development | Purchase | 10,000 | $0.8298 | 115,059 |
| Feb 12, 2026 | Deborah Margaret Browndirector | Purchase | 25,000 | $0.8496 | 109,851 |
| Feb 12, 2026 | Thomas Charles Heinemanofficer: Chief Medical Officer | Purchase | 12,132 | $0.8270 | 282,818 |
| Feb 12, 2026 | Wayne Pisanodirector | Purchase | 30,000 | $0.8446 | 492,414 |
House and Senate disclosures
Not reported.